Novo Nordisk A/S (NYSE:NVO) Shares Purchased by AA Financial Advisors LLC

AA Financial Advisors LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 13.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,194 shares of the company’s stock after buying an additional 389 shares during the period. AA Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $380,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in NVO. Raymond James & Associates boosted its holdings in Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after purchasing an additional 36,223 shares during the last quarter. First Citizens Bank & Trust Co. lifted its holdings in Novo Nordisk A/S by 6.5% in the third quarter. First Citizens Bank & Trust Co. now owns 17,025 shares of the company’s stock valued at $2,027,000 after acquiring an additional 1,039 shares during the last quarter. Blue Trust Inc. grew its position in Novo Nordisk A/S by 41.0% in the third quarter. Blue Trust Inc. now owns 22,703 shares of the company’s stock worth $2,703,000 after acquiring an additional 6,599 shares during the period. Mogy Joel R Investment Counsel Inc. grew its position in Novo Nordisk A/S by 5.1% in the third quarter. Mogy Joel R Investment Counsel Inc. now owns 200,500 shares of the company’s stock worth $23,874,000 after acquiring an additional 9,770 shares during the period. Finally, Net Worth Advisory Group acquired a new stake in Novo Nordisk A/S during the third quarter worth $721,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Down 0.1 %

NYSE NVO opened at $118.09 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market cap of $529.93 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 1.56 and a beta of 0.42. The firm has a 50 day simple moving average of $128.48 and a 200-day simple moving average of $131.69. Novo Nordisk A/S has a one year low of $92.94 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is currently 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.